Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Baxter presents preclincial longer-acting Factor VIII data

Baxter presents preclincial longer-acting Factor VIII data

9th June 2008

Baxter has presented preclincial data for longer-acting factor VIII as a treatment of haemophilia A at the international congress of the World Federation of Haemophilia.

The company presented early-stage data on the pro-drug concept that aims to use pharmacokinetics to lengthen the survival of the molecule through its modificaiton with releasable polyethylene glycol (PEG)-based polymers.

In addition to the information on a releasable PEG conjugate for recombinant factor VIII, the firm also announced data on a partially humanised mouse-model for haemophilia A and the preclinical characterisation of an investigational recombinant blood-free von Willebrand factor.

Hartmut Ehrlich, vice-president of global research and development for bioscience at Baxter, said: “The data presented possibly lay the groundwork for extending our recombinant portfolio to include novel therapies to potentially improve the lives of people with rare blood disorders.”

He added that the company was proud to use its history in haemophilia to pioneer next-generation treatments which will offer improved convenience for patients.

In March 2007, Baxter was granted approval from the Commission of the European Communities to store factor VIII treatment Advate at room temperature for up to two months.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.